Latest Health stories from Life.
Strategic angle: In today's Morning Rounds newsletter, the highlights from #STATBreakthrough, a ruling against Kennedy’s gender-affirming care declaration, and more.
Strategic angle: Exploring expectations around TrumpRx and a new high-dose version of Wegovy.
Strategic angle: Following successful appeals from drugmakers, the U.K. is reviewing the cost-effectiveness of two new Alzheimer's treatments.
Strategic angle: The Broad Institute of MIT and Harvard is poised to receive a massive injection of cash to fund research in the understanding and treatment of bipolar disorder and schizophrenia.
Strategic angle: James Gelfand and Patricia Kelmar argue for urgent reforms to the No Surprises Act to protect patients and employers from financial ruin.
Strategic angle: The farm bill shows politicians catering to the agriculture industry risk losing the support of MAHA while running afoul of public health goals.
Strategic angle: Robert Califf highlights the shift towards political decision-making in the FDA during the Trump administration.
Strategic angle: A U.S. district judge is set to rule against a declaration by Kennedy regarding the medical standards of gender-affirming care for young trans individuals.
Strategic angle: If the U.S. wants to hold on to its title as the world's top biotech innovator, it might want to take a page out of China's book.
Strategic angle: A group of autism scientists kicked off efforts Thursday to influence Congress, and the research agendas of private organizations.
Strategic angle: The Trump administration is counting on its drug pricing efforts to help with the midterm elections.
Strategic angle: A comprehensive timeline of public health policy actions by the Department of Health and Human Services (HHS) under the Trump administration from 2025-2026.
Strategic angle: This page tracks recent state actions to extend Medicaid postpartum coverage.
Strategic angle: Congress has repeatedly extended several pandemic-era flexibilities around Medicare coverage of telehealth, but most remain temporary.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.
Democrats are sharpening their health care message as the midterms loom.
Strategic angle: Eli Lilly's 'triple-G' drug shows potency, In-vivo CAR-T inches toward clinical reality, and more in today's Readout newsletter.
Strategic angle: In this edition of STAT Health Tech: How Apple Watch is being used in a clinical trial for a Parkinson's drug, and more
In today's Morning Rounds newsletter, a Texas couple getting rich off out-of-network medical bills, two doctors on the challenges of medicine today, and more.
Strategic angle: Diabetes patients taking an investigational drug from Eli Lilly saw significant reductions in their blood sugar and weight in a late-stage study.